The Tumor Suppressor CYLD Interacts with TRIP and Regulates Negatively Nuclear Factor κB Activation by Tumor Necrosis Factor
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Cylindromas are benign adnexal skin tumors caused by germline mutations in the CYLD gene. In most cases the second wild-type allele is lost in tumor tissue, suggesting that CYLD functions as tumor suppressor. CYLD is a protein of 956 amino acids harboring a functional deubiquitinating domain at the COOH-terminal end. To shed more light on the function of CYLD, we have performed a yeast two hybrid screen using an HaCaT cDNA library that identified the RING finger protein TRIP (TRAF-interacting protein) as interactor with full-length CYLD. Mapping of the interacting domains revealed that the central domain of CYLD binds to the COOH-terminal end of TRIP. Far Western analysis and coimmunoprecipitations in mammalian cells confirmed that full-length CYLD binds to the COOH-terminal domain of TRIP. Because TRIP is an inhibitor of nuclear factor (NF)-κB activation by tumor necrosis factor (TNF), the effect of CYLD on NF-κB activation was investigated in HeLa cells. The results established that CYLD down-regulates NF-κB activation by TNF-α. The inhibition by CYLD depends on the presence of the central domain interacting with TRIP and its deubiquitinating activity. These findings indicate that cylindromas arise through constitutive NF-κB activation leading to hyperproliferation and tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemistry-Based Functional Proteomics Reveals Novel Members of the Deubiquitinating Enzyme Family
Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson, K. D., Ploegh, H. L., & Kessler, B. M. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00248-x · Cited by 588 · cited 1×
“This enzymatic activity of CYLD was confirmed by a chemistry-based approach (14), indicating that CYLD could deubiquitinate target proteins.”
BackgroundNF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia
Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y., et al. (2003) · Nature · doi:10.1038/nature01283 · Cited by 535 · cited 1×
“Furthermore, coexpression of an oncogenic Ras mutant and the mutant I B cooperated to form highly invasive squamous cell carcinomas in human epidermal keratinocyte grafts (25).”
BackgroundMonreal, A. W., Ferguson, B. M., Headon, D. J., Street, S. L., Overbeek, P. A., & Zonana, J. (1999) · Nature Genetics · doi:10.1038/11937 · Cited by 397
Involvement of a novel Tnf receptor homologue in hair follicle induction.
Headon, D. J., & Overbeek, P. A. (1999) · Nature Genetics · doi:10.1038/11943 · Cited by 379 · cited 1×
“In humans, congenital deficiencies of sweat glands and hair are known in patients suffering from hypoor anhydrotic ectodermal dysplasia, which are caused by mutations in EDAR or EDA genes (29, 30).”
BackgroundGene defect in ectodermal dysplasia implicates a death domain adapter in development
Headon, D. J., Emmal, S. A., Ferguson, B. M., Tucker, A. S., Justice, M. J., Sharpe, P. T., Zonana, J., & Overbeek, P. A. (2001) · Nature · doi:10.1038/414913a · Cited by 378 · cited 3×
“Furthermore, TRIP together with CYLD could negatively regulate EDA/ EDAR/EDARADD signaling because EDARADD interacts with TRAF1, TRAF2, and TRAF3 (28).”
Background
Cited by
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Prioritizing candidate disease genes by network-based boosting of genome-wide association data
Lee, I., Blom, U. M., Wang, P. I., Shim, J. E., & Marcotte, E. M. (2011) · Genome Research · doi:10.1101/gr.118992.110 · Cited by 686
IκB kinase complexes: gateways to NF-κB activation and transcription
Scheidereit, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209934 · Cited by 651
Mutations in the NF-κB signaling pathway: implications for human disease
Courtois, G., & Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209939 · Cited by 525
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling
Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., & Fässler, R. (2006) · Cell · doi:10.1016/j.cell.2006.03.041 · Cited by 476
CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes
Sun, S.-C. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.43 · Cited by 400
MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling
Liang, J., Saad, Y., Lei, T., Wang, J., Qi, D., Yang, Q., Kolattukudy, P. E., & Fu, M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092641 · Cited by 297
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., & Kuehl, W. M. (2010) · Blood · doi:10.1182/blood-2009-09-243535 · Cited by 288
Reiley, W. W., Jin, W., Lee, A. J., Wright, A., Wu, X., Tewalt, E. F., Leonard, T. O., Norbury, C. C., Fitzpatrick, L., Zhang, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062694 · Cited by 254
Regulation of T cell development by the deubiquitinating enzyme CYLD
Reiley, W. W., Zhang, M., Jin, W., Losiewicz, M., Donohue, K. B., Norbury, C. C., & Sun, S.-C. (2006) · Nature Immunology · doi:10.1038/ni1315 · Cited by 198
Targeting ubiquitin specific proteases for drug discovery
Daviet, L., & Colland, F. (2008) · Biochimie · doi:10.1016/j.biochi.2007.09.013 · Cited by 126
Metadata
- Authors
- Regamey, A., Hohl, D., Liu, J. W., Roger, T., Kogerman, P., Toftgård, R., & Huber, M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-12-15
- Volume
- 198
- Issue
- 12
- Pages
- 1959-1964
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2148641114
- Cited by
- 117
- References
- 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.